Trial Profile
A Double-Blind, Randomized, Placebo-Controlled Efficacy and Safety Study of DVS-233 SR For Relief of Vasomotor Symptoms Associated With Menopause
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Menopause; Vasomotor symptoms
- Focus Therapeutic Use
- Sponsors Wyeth
- 17 Oct 2007 Results presented at ASRM 2007.
- 09 May 2007 Results have been published.
- 10 Jan 2007 New trial record.